Telemedicine for patients with rheumatic diseases: systematic review and proposal for research agenda

M Piga, I Cangemi, A Mathieu, A Cauli - Seminars in Arthritis and …, 2017 - Elsevier
Objective To systematically review the scientific literature regarding tele-rheumatology and
draw conclusions about feasibility, effectiveness, and patient satisfaction. Methods PubMed, …

International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid …

…, O Berardicurti, F Carubbi, A Cauli… - Autoimmunity …, 2017 - Elsevier
Autoimmune diseases are a complex set of diseases characterized by immune system
activation and, although many progresses have been done in the last 15 years, several unmet …

Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases: systematic literature review and analysis of a monocentric cohort

M Piga, E Chessa, V Ibba, V Mura, A Floris, A Cauli… - Autoimmunity …, 2014 - Elsevier
The use of biologic drugs has been linked with the paradoxical development of systemic and
organ specific autoimmune processes. The aim of this study was to describe the features of …

Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis

…, WH Boehncke, W Campbell, A Cauli… - Arthritis & …, 2016 - Wiley Online Library
Objective To update the 2009 Group for Research and Assessment of Psoriasis and Psoriatic
Arthritis (GRAPPA) treatment recommendations for the spectrum of manifestations affecting …

The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide

…, D Abramovicz, D Blockmans, A Cauli… - Annals of the …, 2010 - ard.bmj.com
Objective: To update the follow-up of the Euro-Lupus Nephritis Trial (ELNT), a randomised
prospective trial comparing low-dose (LD) and high-dose (HD) intravenous (IV) …

Consensus on a core set of domains for psoriatic arthritis.

…, W Taylor, A Adebajo, J Braun, A Cauli… - The Journal of …, 2007 - jrheum.org
A psoriatic arthritis (PsA) module was convened at OMERACT 8 in order to achieve
consensus on the core domains that should be included in randomized controlled trials and …

[HTML][HTML] Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven …

…, S Kelly, PP Sainaghi, N Gendi, B Dasgupta, A Cauli… - The Lancet, 2021 - thelancet.com
Background Although targeted biological treatments have transformed the outlook for
patients with rheumatoid arthritis, 40% of patients show poor clinical response, which is …

The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)

…, VF Azevedo, AB Ostos, S Carneiro, A Cauli… - Annals of the …, 2013 - ard.bmj.com
Objective To develop new composite disease activity indices for psoriatic arthritis (PsA).
Methods Data from routine clinic visits at multiple centres were collected in a systematic manner. …

[PDF][PDF] Molecular portraits of early rheumatoid arthritis identify clinical and treatment response phenotypes

…, R Landewé, A van der Helm-van Mil, A Cauli… - Cell reports, 2019 - cell.com
There is a current imperative to unravel the hierarchy of molecular pathways that drive the
transition of early to established disease in rheumatoid arthritis (RA). Herein, we report a …

Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients

…, A van der Helm-van Mil, A Cauli… - Annals of the …, 2019 - ard.bmj.com
Objectives To unravel the hierarchy of cellular/molecular pathways in the disease tissue of
early, treatment-naïve rheumatoid arthritis (RA) patients and determine their relationship with …